Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 99

1.

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators..

J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.

2.

MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure.

Beaumont J, López B, Ravassa S, Hermida N, José GS, Gallego I, Valencia F, Gómez-Doblas JJ, de Teresa E, Díez J, González A.

Sci Rep. 2017 Jan 16;7:40696. doi: 10.1038/srep40696.

3.

Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients.

Gallego I, Beaumont J, López B, Ravassa S, Gómez-Doblas JJ, Moreno MU, Valencia F, de Teresa E, Díez J, González A.

Clin Sci (Lond). 2016 Dec 1;130(23):2139-2149. Epub 2016 Sep 13.

PMID:
27624142
4.

Fibrillin 2 is upregulated in the ascending aorta of patients with bicuspid aortic valve.

Rueda-Martínez C, Lamas O, Mataró MJ, Robledo-Carmona J, Sánchez-Espín G, Moreno-Santos I, Carrasco-Chinchilla F, Gallego P, Such-Martínez M, de Teresa E, Jiménez-Navarro M, Fernández B.

Eur J Cardiothorac Surg. 2017 Jan;51(1):104-111. doi: 10.1093/ejcts/ezw277. Epub 2016 Sep 15.

PMID:
27634926
5.

Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.

Robles-Mezcua A, González-Cruces N, Ruiz-Salas A, Morcillo-Hidalgo L, Robledo-Carmona J, Gómez-Doblas JJ, de Teresa E, García-Pinilla JM.

Int J Cardiol. 2016 Jan 1;202:118-20. doi: 10.1016/j.ijcard.2015.08.204. Epub 2015 Sep 1. No abstract available.

PMID:
26397399
6.

Late presentation of traumatic aortic regurgitation.

López-Garrido M, Ruiz-Salas A, Carrasco-Chinchilla F, Rodriguez-Bailón I, Morillo E, Gómez-Doblas JJ, de Teresa E.

Int J Cardiol. 2015 Nov 15;199:389-90. doi: 10.1016/j.ijcard.2015.06.077. Epub 2015 Jul 21. No abstract available.

PMID:
26247795
7.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators..

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

8.

Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.

Ruiz-Salas A, García-Pinilla JM, Cabrera-Bueno F, Fernández-Pastor J, Peña-Hernández J, Medina-Palomo C, Barrera-Cordero A, De Teresa E, Alzueta J.

Europace. 2016 May;18(5):773-7. doi: 10.1093/europace/euv079. Epub 2015 Apr 7.

PMID:
25855675
9.

Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction.

López-Ruiz E, Perán M, Picón-Ruiz M, García MA, Carrillo E, Jiménez-Navarro M, Hernández MC, Prat I, De Teresa E, Marchal JA.

Cytotherapy. 2014 Sep;16(9):1229-37. doi: 10.1016/j.jcyt.2014.05.012. Epub 2014 Jun 23.

PMID:
24969968
10.

Short- and long-term outcomes of surgery for severe tricuspid regurgitation.

Rodríguez-Capitán J, Gómez-Doblas JJ, Fernández-López L, López-Salguero R, Ruiz M, Leruite I, Cabrera-Bueno F, Mataró-López MJ, Sánchez-Espín G, Melero-Tejedor JM, Porras-Martín C, Such M, de Teresa E.

Rev Esp Cardiol (Engl Ed). 2013 Aug;66(8):629-35. doi: 10.1016/j.rec.2013.02.002. Epub 2013 May 25.

PMID:
24776331
11.

microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation.

Beaumont J, López B, Hermida N, Schroen B, San José G, Heymans S, Valencia F, Gómez-Doblas JJ, De Teresa E, Díez J, González A.

Clin Sci (Lond). 2014 Apr;126(7):497-506. doi: 10.1042/CS20130538.

PMID:
24168656
12.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators..

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
13.

Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy.

Stockburger M, de Teresa E, Lamas G, Desaga M, Koenig C, Habedank D, Cobo E, Navarro X, Wiegand U.

Europace. 2014 Jan;16(1):63-70. doi: 10.1093/europace/eut217. Epub 2013 Jul 16.

PMID:
23861381
14.

Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis.

Moreno MU, Gallego I, López B, González A, Fortuño A, San José G, Valencia F, Gómez-Doblas JJ, de Teresa E, Shah AM, Díez J, Zalba G.

Clin Sci (Lond). 2013 Sep;125(6):291-300. doi: 10.1042/CS20120612.

PMID:
23550626
15.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees.; RED-HF Investigators..

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

16.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators..

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

17.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators..

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

18.

Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers.

Anguita M, Castillo JC, Ruiz M, Castillo F, Jiménez-Navarro M, Crespo M, Alonso-Pulpón L, de Teresa E, Castro-Beiras A, Roig E, Artigas R, Zapata A, de Ullibarri IL, Muñiz J; OBELICA Study Researchers..

Rev Esp Cardiol (Engl Ed). 2012 Jan;65(1):22-8. doi: 10.1016/j.recesp.2011.07.011. Epub 2011 Oct 15. English, Spanish.

PMID:
22001308
19.

Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study.

TORAFIC Investigators Group..

Clin Ther. 2011 Sep;33(9):1204-1213.e3. doi: 10.1016/j.clinthera.2011.08.006. Epub 2011 Sep 8.

PMID:
21906812
20.

Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF).

Stockburger M, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-López F, de Teresa E.

Eur J Heart Fail. 2011 Jun;13(6):633-41. doi: 10.1093/eurjhf/hfr041.

Supplemental Content

Loading ...
Support Center